QSAM Biosciences (QSAM Biosciences) EBIT : $-4.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is QSAM Biosciences EBIT?

QSAM Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-0.53 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. QSAM Biosciences's annualized ROC % for the quarter that ended in Dec. 2023 was -25,600.00%. QSAM Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. QSAM Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -11.09%.

QSAM Biosciences EBIT Historical Data

The historical data trend for QSAM Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QSAM Biosciences EBIT Chart

QSAM Biosciences Annual Data

Trend

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-0.09

-4.83

-11.19

-5.48

-4.00

QSAM Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-1.23	-1.07	-1.24	-1.16	-0.53

Competitive Comparison of QSAM Biosciences's EBIT

For the Biotechnology subindustry, QSAM Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

QSAM Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QSAM Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where QSAM Biosciences's EV-to-EBIT falls into.

QSAM Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.00 Mil.

QSAM Biosciences (OTCPK:QSAM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

QSAM Biosciences's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-1.92 * ( 1 - 0% )	/	( (0.0070000000000001	+	0.008)	/ 2 )
=	-1.92	/	0.0075000000000001
=	-25,600.00 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.61	-	1.703	-	( 0.447	-	max(0, 1.71	-	0.61	+	0.447	))
=	0.0070000000000001

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.705	-	1.025	-	( 1.386	-	max(0, 1.033	-	1.705	+	1.386	))
=	0.008

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

QSAM Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-2.128	/	( ( (0 + max(-1.639, 0))	+	(0 + max(-0.706, 0)) )	/	2 )
=	-2.128	/	( ( 0	+	0 )	/	2 )
=	-2.128	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.063)	-	(1.703	+	0	+	-0.0010000000000001)
=	-1.639

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.319)	-	(1.025	+	0	+	0)
=	-0.706

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

QSAM Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-3.995	/	36.028
	=	-11.09 %

QSAM Biosciences EBIT Related Terms

Thank you for viewing the detailed overview of QSAM Biosciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

QSAM Biosciences (QSAM Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » QSAM Biosciences Inc (OTCPK:QSAM) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

9442 Capital of Texas Highway North, Plaza 1, Suite 500, Austin, TX, USA, 78759

Website

https://www.qsambio.com

QSAM Biosciences Inc is a clinical-stage novel radiopharmaceutical company. The company is developing treatments for bone cancer and related diseases.

Executives

Adam King	officer: Chief Financial Officer	9442 CAPITAL OF TEXAS HWY N, PLAZA 1, SUITE 500, AUSTIN TX 78759
Link Jr. Charles J	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Adriann Sax	director	7 DORSET COURT,, EAST BRUNSWICK, NJ 08816
David Charles Link	director	2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Douglas R Baum	director, officer: CEO & Director	5000 RAFFEE COVE, AUSTIN TX 78731-1132
C Richard Piazza	director, officer: Executive Chairman	2236 EAST MALL, SUITE 208, UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER A1 V6T 1Z3
Checkmate Strategic Capital Holdings, Llc	other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Strategic Capital 2, Llc	10 percent owner, other: See Explanation of Responses	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Capital Group, Llc	10 percent owner, other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Charles Thomas Paschall	other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Christopher M. Nelson	director, officer: General Counsel	420 ROYAL PALM WAY, SUITE #100, PALM BEACH FL 33480
Scott W. Whitney	director, other: Former Director	96 WINDSOR DRIVE, PINE BROOK NJ 07058
Kevin Bolin	director, officer: Former Chairman & CEO	1081 ROSEDALE DRIVE, ATLANTA GA 30306
Tristan Peitz	director, other: Former Director	C/O Q2POWER TECHNOLOGIES, INC., 420 ROYAL PALM WAY, #100, PALM BEACH FL 33480
Joel David Mayersohn	director	350 EAST LAS OLAS BLVD. #1150, FORT LAUDERDALE FL 33301